Blue Ledge Capital

Blue Ledge Capital is a venture capital firm founded in 2020 and located in Larkspur, California. The firm focuses on investing in early-stage companies, providing them with the necessary capital and support to drive growth and innovation. Blue Ledge Capital aims to identify and partner with promising entrepreneurs and startups, fostering the development of new ideas and business models across various sectors. Its strategic approach combines financial investment with hands-on guidance, helping portfolio companies navigate challenges and achieve their objectives.

Andrew Roche

Founder and Chief Investment Officer

3 past transactions

Qnovia

Series B in 2024
Qnovia is a biotechnology company that specializes in developing innovative drug delivery systems, focusing particularly on inhalation-based technologies. The company aims to enhance the delivery of a wide range of pharmaceuticals, including nicotine, by creating advanced aerosol devices and formulations that address the limitations of traditional drug delivery methods. Qnovia's platform not only seeks to improve patient outcomes through more effective inhaled therapies but also emphasizes responsible sourcing and transparency in product information. By prioritizing innovation and patient-centric solutions, Qnovia strives to contribute positively to public health and the overall experience of medication delivery.

AvantGuard

Seed Round in 2023
AvantGuard creats innovative solutions that manage surfaces and provide long-term protection against viruses, bacteria, and fungi/mold, in a variety of applications.

Qnovia

Series A in 2022
Qnovia is a biotechnology company that specializes in developing innovative drug delivery systems, focusing particularly on inhalation-based technologies. The company aims to enhance the delivery of a wide range of pharmaceuticals, including nicotine, by creating advanced aerosol devices and formulations that address the limitations of traditional drug delivery methods. Qnovia's platform not only seeks to improve patient outcomes through more effective inhaled therapies but also emphasizes responsible sourcing and transparency in product information. By prioritizing innovation and patient-centric solutions, Qnovia strives to contribute positively to public health and the overall experience of medication delivery.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.